Hypertension Prevalence, Awareness, and Control in US Adults Before and After the COVID-19 Pandemic

IF 2.5 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Clinical Hypertension Pub Date : 2025-07-20 DOI:10.1111/jch.70093

Mohammed Essa, Devesh Malik, Yuan Lu, Huanhuan Yang, Erica S. Spatz, Harlan M. Krumholz, Kamil F. Faridi

{"title":"Hypertension Prevalence, Awareness, and Control in US Adults Before and After the COVID-19 Pandemic","authors":"Mohammed Essa, Devesh Malik, Yuan Lu, Huanhuan Yang, Erica S. Spatz, Harlan M. Krumholz, Kamil F. Faridi","doi":"10.1111/jch.70093","DOIUrl":null,"url":null,"abstract":"Hypertension is a leading cause of death and disability in the United States, but national trends in hypertension after the COVID-19 pandemic remain unknown. We analyzed NHANES data from pre-pandemic (2017–March 2020) and post-pandemic (August 2021–August 2023) surveys to determine nationwide prevalence, awareness, and control of hypertension. Weighted, age-standardized prevalence estimates were compared using Poisson regression with prevalence ratios (PRs). Among 14 449 participants representing 237 million US adults, hypertension prevalence was 49.5% pre-pandemic versus 47.7% post-pandemic (PR 0.96; p = 0.15). Overall, hypertension awareness was unchanged (57.7% vs. 53.7%; PR 0.96; p = 0.14) but declined among adults aged 18–39 years (PR 0.78; p = 0.02). Blood pressure control remained low (25.9% vs. 22.3%; PR 0.91; p = 0.06) and worsened in men (PR 0.83; p = 0.01). In conclusion, hypertension prevalence, awareness, and control did not significantly improve post-pandemic. More aggressive public health efforts are needed to reduce the adverse impacts of hypertension in the United States.","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"27 7","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.70093","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Hypertension","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jch.70093","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Hypertension is a leading cause of death and disability in the United States, but national trends in hypertension after the COVID-19 pandemic remain unknown. We analyzed NHANES data from pre-pandemic (2017–March 2020) and post-pandemic (August 2021–August 2023) surveys to determine nationwide prevalence, awareness, and control of hypertension. Weighted, age-standardized prevalence estimates were compared using Poisson regression with prevalence ratios (PRs). Among 14 449 participants representing 237 million US adults, hypertension prevalence was 49.5% pre-pandemic versus 47.7% post-pandemic (PR 0.96; p = 0.15). Overall, hypertension awareness was unchanged (57.7% vs. 53.7%; PR 0.96; p = 0.14) but declined among adults aged 18–39 years (PR 0.78; p = 0.02). Blood pressure control remained low (25.9% vs. 22.3%; PR 0.91; p = 0.06) and worsened in men (PR 0.83; p = 0.01). In conclusion, hypertension prevalence, awareness, and control did not significantly improve post-pandemic. More aggressive public health efforts are needed to reduce the adverse impacts of hypertension in the United States.

Abstract Image

查看原文本刊更多论文

COVID-19大流行前后美国成年人高血压患病率、意识和控制

在美国，高血压是导致死亡和残疾的主要原因，但2019冠状病毒病大流行后，全国高血压趋势尚不清楚。我们分析了大流行前（2017 - 2020年3月）和大流行后（2021年8月- 2023年8月）调查的NHANES数据，以确定全国范围内高血压的患病率、意识和控制。加权、年龄标准化的患病率估计值使用泊松回归与患病率比（pr）进行比较。在代表2.37亿美国成年人的14449名参与者中，高血压患病率在大流行前为49.5%，在大流行后为47.7% (PR = 0.96；p = 0.15)。总体而言，高血压意识没有变化(57.7% vs. 53.7%；公关0.96;p = 0.14)，但在18-39岁的成年人中有所下降(PR = 0.78；p = 0.02)。血压控制仍然很低(25.9% vs. 22.3%；公关0.91;p = 0.06)，男性加重(PR 0.83；p = 0.01)。总之，大流行后高血压的患病率、意识和控制没有显著改善。在美国，需要更积极的公共卫生努力来减少高血压的不利影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Hypertension PERIPHERAL VASCULAR DISEASE-

CiteScore

5.80

自引率

7.10%

发文量

191

审稿时长

4-8 weeks

期刊介绍： The Journal of Clinical Hypertension is a peer-reviewed, monthly publication that serves internists, cardiologists, nephrologists, endocrinologists, hypertension specialists, primary care practitioners, pharmacists and all professionals interested in hypertension by providing objective, up-to-date information and practical recommendations on the full range of clinical aspects of hypertension. Commentaries and columns by experts in the field provide further insights into our original research articles as well as on major articles published elsewhere. Major guidelines for the management of hypertension are also an important feature of the Journal. Through its partnership with the World Hypertension League, JCH will include a new focus on hypertension and public health, including major policy issues, that features research and reviews related to disease characteristics and management at the population level.